Table 1. Patient characteristics at... | American Society of Hematology

Table 1.

Patient characteristics at study entry

Characteristic	Initial registration		FAMP therapy
Characteristic	All patients, % (n = 231)	Observation longer than 1 y, % (n = 54)	Overall, % (n = 182)	No prior therapy, % (n = 118)	Prior therapy, % (n = 64)
Age at least 70 y	35	43	33	29	41
Men	59	63	58	58	56
Performance status greater than 1	8	4^*	9	7	13
Disease duration longer than 1 y	34	25	39	19	76^†
Fatigue	56	13^*	70	68	75
Dizziness	16	0^*	21	21	21
Visual disturbance	12	2^*	14	13	16
Bleeding	19	4^*	24	27	17
Infection	5	2	5	5	5
Lymphadenopathy	19	4^*	24	30	14^†
Hepatomegaly	8	0^*	10	12	6
Splenomegaly	17	2^*	22	26	14

Characteristic	Initial registration		FAMP therapy
Characteristic	All patients, % (n = 231)	Observation longer than 1 y, % (n = 54)	Overall, % (n = 182)	No prior therapy, % (n = 118)	Prior therapy, % (n = 64)
Age at least 70 y	35	43	33	29	41
Men	59	63	58	58	56
Performance status greater than 1	8	4^*	9	7	13
Disease duration longer than 1 y	34	25	39	19	76^†
Fatigue	56	13^*	70	68	75
Dizziness	16	0^*	21	21	21
Visual disturbance	12	2^*	14	13	16
Bleeding	19	4^*	24	27	17
Infection	5	2	5	5	5
Lymphadenopathy	19	4^*	24	30	14^†
Hepatomegaly	8	0^*	10	12	6
Splenomegaly	17	2^*	22	26	14

FAMP indicates fludarabine.

P < .05 compared with group registering for treatment step within 1 year of registration for initial step.

P < .05 compared with no-prior-therapy group.